Clinical trials: HCM - Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive…
- Trial name
- CMI-SWITCH (NCT07600177)
- Testing
- Aficamten
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Hypertrophic Cardiomyopathy, Depression
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression
- Conditions
- Hypertrophic Cardiomyopathy, Depression, Anxiety, Psychotherapy
- Trial name
- NCT03706001
- Testing
- Psychotherapy
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Hypertrophic Cardiomyopathy
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and…
- Trial name
- VANISH (NCT01912534)
- Testing
- Valsartan
- Where
- 15 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Carelon Research
Hypertrophic Cardiomyopathy
Diagnosis of HCM With AI-ECG
The study aims to establish a diagnostic model of hypertrophic cardiomyopathy with artificial intelligence-enhanced electrocardiogram.
- Trial name
- NCT06287892
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Hypertrophic Cardiomyopathy
Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
A heart condition called hypertrophic cardiomyopathy (HCM) causes abnormal thickening of the heart muscle, which obstructs the flow of blood out of the heart.
- Trial name
- NCT00001960
- Testing
- Pacemaker therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy (HCM)
ReGistry of hypeRtrophic cArDIomyopathy: Regional fEatures, geNeTics and Course
This study is envisioned as the very first of its kind in the Russian Federation, aiming to provide a comprehensive characterization of the clinical spectrum and disease burden, focusing on the epidemiology and progression of HCM…
- Trial name
- GRADIENT (NCT07295613)
- Where
- 2 sites in Russia
- Volunteers
- 1,400 people
- Sponsor
- Central State Medical Academy
Hypertrophic Cardiomyopathy (HCM)
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest.
- Trial name
- LA-HCM (NCT07202897)
- Testing
- Anticoagulant treatment Rivaroxaban, Best medical therapy
- Where
- 17 sites in France
- Volunteers
- 532 people
- Sponsor
- Rennes University Hospital
Obstructive Hypertrophic Cardiomyopathy
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea.
- Trial name
- NCT06146660
- Testing
- Mavacamten
- Where
- 2 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Non-Invasive Radiation Ablation in Patients With Hypertrophic CardioMyopathy: NIRA-HOCM
Hypertrophic cardiomyopathy (HCM) is a common disease of the heart which causes thickening of the heart muscle. HCM primarily affects the muscle of the main pumping chamber of the heart (the left ventricle) and particularly the…
- Trial name
- NIRA-HOCM (NCT04153162)
- Testing
- Stereotactic body radiation therapy
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Barts & The London NHS Trust
Coronary Artery Disease, Heart Failure
Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD.
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Congenital Heart Disease
- Trial name
- SE2030 (NCT05081115)
- Testing
- ABCDE-Stress Echo, SE diastolic assessment, SE Right ventricular function assessment
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Fatebenefratelli Hospital
Hypertrophic Cardiomyopathy With Obstruction
Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY
This investigation is a prospective, randomized, single-blinded and multicenter design. The purpose of this study is to evaluate the benefit of atrial-synchronous biventricular (BiV) pacing in severely symptomatic hypertrophic…
- Trial name
- TRICHAMPION (NCT01614717)
- Testing
- CRT-P Implant
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Abbott Medical Devices
Hypertrophic Cardiomyopathy
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
The overall aim of this project is to establish potential benefits of a novel lifestyle (physical activity and dietary nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor) interventions in patients with…
- Trial name
- SILICOFCM (NCT05366101)
- Testing
- Sacubitril/Valsartan, Lifestyle
- Where
- United Kingdom
- Volunteers
- 168 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Hypertrophic Cardiomyopathy
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy
Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.
- Trial name
- PRIMARy (NCT02994615)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia
Extended ECG Monitoring in HCM Patients
The purpose of this study is to determine, among a large cohort of 300 consecutive patients with hypertrophic cardiomyopathy, if extended ambulatory monitoring using the iRhythm Technologies, Inc.
- Conditions
- Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation
- Trial name
- EXAMINE-HCM (NCT04056715)
- Testing
- Zio XT
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- iRhythm Technologies, Inc.
Obstructive Hypertrophic Cardiomyopathy
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac…
- Trial name
- NCT06116968
- Testing
- Aficamten
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Corxel Pharmaceuticals